Noctamide

Quick links to important sections

Noctamide

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noctamide

Quick Facts (Lormetazepam)

Property Description
Active Ingredient Lormetazepam
Pharmacological Class Benzodiazepine (Sedative-Hypnotic)
Typical Form Oral Tablets
Common Use Short-term treatment of severe Insomnia
Regulatory Status Prescription-Only

Noctamide: Identity and Core Purpose

Noctamide is a former brand name for a prescription-only sedative-hypnotic drug containing the active ingredient Lormetazepam. It is formulated as an oral tablet and is specifically licensed for the short-term management of severe insomnia when sleeplessness is debilitating or causing extreme personal distress.

Lormetazepam is used for the short-term management of sleep disorders. The medication is designed to quickly facilitate sleep onset and maintenance for individuals experiencing acute sleep disturbances, such as those caused by intense stress or anxiety.


What Type of Drug is Lormetazepam?

The chemical substance Lormetazepam is classified within the benzodiazepine pharmacological class, a group of medicines that act as central nervous system (CNS) depressants. It is a synthetic compound, manufactured to interact specifically with neurotransmitters in the brain.

Lormetazepam is recognized for its short-to-intermediate-acting half-life, which makes it particularly useful as a sleep aid. This specific kinetic profile helps promote sleep onset while aiming to minimize residual daytime sleepiness, a common side effect of longer-acting sedative agents.


Therapeutic Role: Addressing Acute Sleep Disorders

The primary therapeutic role of products containing Lormetazepam is the rapid, temporary resolution of clinically significant insomnia. However, its usage is strictly limited to a brief duration, typically no more than two to four weeks. This essential restriction is in place to mitigate the substantial risk of developing tolerance and physical dependence often associated with the chronic use of hypnotic benzodiazepines.

What side effects are possible with Noctamide?

Possible Side Effects and Safety Information

The safety profile of Lormetazepam (Noctamide) is officially structured by government regulatory agencies based on its function as a central nervous system (CNS) depressant. The potential adverse reactions are formally categorized by both frequency and the organ system affected, as documented in regulatory prescribing information.

Common and Expected Adverse Reactions

The most frequently listed side effects, classified as Common (affecting 1 to 10 users in 100), are primarily related to the drug's sedative effects. These include daytime drowsiness (somnolence), dizziness, muscle weakness, and fatigue. Effects such as unsteadiness (ataxia) are also categorized as common and contribute to the risk profile, particularly in certain populations.

Serious Adverse Reactions and Safety Constraints

Regulatory documents emphasize the potential for serious outcomes, most notably the risk of physical and psychological dependence and the subsequent development of a severe withdrawal syndrome upon cessation. This risk increases with the duration of use. The potential for anterograde amnesia (impaired memory for recent events) is also documented, occurring most often shortly after administration.

Clinically significant effects include respiratory depression, especially when Lormetazepam is combined with other CNS depressants such as alcohol or opioids. Rare but severe paradoxical reactions (e.g., agitation, aggression, rage) have also been reported.

Population-Specific and Time-Related Safety Notes

Specific cautions are noted for special populations. Older adults face an increased risk of falls and hip fractures due to common adverse effects like dizziness and ataxia. Use in patients with severe hepatic impairment is officially contraindicated due to the risk of precipitating encephalopathy. The official safety documentation specifies that effects like somnolence are most likely to occur at the beginning of treatment.

Regulatory Safety Classifications

The safety profile is anchored by the risk of dependence, which is a primary constraint on its short-term use. The drug is formally contraindicated in conditions such as myasthenia gravis and severe hepatic failure.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents define Lormetazepam overdose as an over-extension of its Central Nervous System (CNS) depressant effects. Documented manifestations begin with symptoms such as pronounced drowsiness, ataxia (loss of coordination), slurred speech, and hypotonia, which can progress to a stuporous or comatose state.

Officially, the most serious risks involve the respiratory and circulatory systems. Severe overdose is associated with respiratory depression, hypotension (low blood pressure), and the risk of respiratory arrest or death. Regulatory information specifically highlights this risk when the medication is consumed in combination with other CNS depressants, notably alcohol or opioids.

Authorities mandate that you seek immediate medical attention or contact emergency services if an overdose is suspected, or if signs of profound sedation or difficulty breathing are observed. Management in a medical setting is centered on symptomatic and supportive treatment, including necessary airway management. The specific benzodiazepine antagonist, Flumazenil, is available for consideration for the reversal of effects.

Regulatory documentation also advises that elderly patients and individuals with impaired renal or hepatic function require closer observation, as they face an increased risk of severe and prolonged outcomes following an overdose.

Therapeutic Uses of Noctamide

What Noctamide Treats: Main Uses and Benefits

Lormetazepam (Noctamide) is commonly used in situations involving certain distressing symptoms where the primary goal is the rapid, temporary easing of debilitating sleep loss, focusing strictly on supportive symptomatic relief. This medication is applied across domains where short-term symptom management is appropriate. It is used in situations characterized by severe sleep disturbances, including difficulty falling asleep (sleep onset latency) and frequent nocturnal awakenings (sleep maintenance problems).


The medication is relevant in clinical settings marked by acute situational insomnia, often triggered by high emotional tension or sudden life changes. By providing supportive, short-term symptomatic assistance, Lormetazepam may help patients cope more steadily with difficult episodes. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

This medication is typically reserved for sleep disturbances considered severe and clinically significant.


Quick Fact: Relief for Acute Insomnia

Symptom Domain Therapeutic Role
Sleep Initiation Supports rapid transition to sleep.
Nocturnal Wakefulness Helps maintain sleep continuity.
Severity Used for severe, debilitating episodes.

Eligibility and Restrictions for Use

The regulatory eligibility profile for Lormetazepam (Noctamide) is strictly defined by governmental labeling, detailing which populations are permitted, restricted, or prohibited from using the medicine.

Contraindicated Populations

Use is absolutely contraindicated in patients presenting with several severe underlying conditions, as stated in official labeling. This includes individuals with severe respiratory insufficiency, severe hepatic insufficiency (due to the risk of encephalopathy), Myasthenia Gravis, or Sleep Apnoea Syndrome. The medicine is also prohibited for patients with known hypersensitivity to Lormetazepam or any benzodiazepine.

Restricted Use and Limitations

  • Age-Related: Lormetazepam should not be given to patients under 18 years of age as safety and efficacy are not established for this group. Older adults must receive a reduced starting dose due to documented increased sensitivity.
  • Physiological Status: The medicine should not be used during pregnancy or lactation, as officially stated by regulatory bodies.
  • Comorbidities: Use requires caution and monitoring, often with reduced doses, in patients with mild to moderate hepatic or renal insufficiency. Additionally, use should be avoided in individuals with a history of alcohol or drug dependence.

What should I know about interactions with other medicines?

Lormetazepam's interaction profile is defined primarily by its pharmacodynamic effects, involving an additive increase in central nervous system (CNS) depression when combined with other substances or medicines. The regulatory restrictions focus on mitigating the risks associated with this combined sedation.

Interactions with CNS Depressants

Co-administration with other agents that depress CNS function can result in significantly enhanced effects. These agents include antipsychotics, barbiturates, other sedatives, anxiolytics, and antidepressant medicines.

  • Opioids: The combination of Lormetazepam and opioids carries a risk of profound sedation, respiratory depression, coma, and death due to their additive effects. Regulatory documentation specifies that the dosage and duration of this concomitant use must be strictly limited.
  • Alcohol: Consumption of alcohol must be avoided as it is documented to enhance the sedative effects of Lormetazepam.

Other Interactions

  • Muscle Relaxants can produce an accumulative muscle-relaxing effect. This interaction warrants specific caution in elderly patients due to an associated increased risk of falling.
  • The sedative effects of Lormetazepam may be reduced when co-administered with theophylline or aminophylline.
  • An enhanced hypotensive effect may occur when Lormetazepam is used concurrently with antihypertensive agents.
  • Compounds that inhibit hepatic enzymes, such as certain CYP450 inhibitors, are documented as potentially enhancing the activity of Lormetazepam, although this applies to a lesser degree due to the drug’s primary metabolic pathway.

Mechanism of Action

How Noctamide Works

Noctamide is a positive allosteric modulator of the GABA A receptor complex. It binds to a specific site distinct from that of the endogenous neurotransmitter GABA. The compound exhibits selectivity for GABA A receptor subtypes that contain alpha1, beta2, and gamma2 subunits, primarily situated within the reticular activating system and thalamic structures. This allosteric interaction enhances the binding affinity of GABA, leading to an increase in the frequency of chloride ion channel opening. The resulting inward flux of negatively charged chloride ions induces hyperpolarization across the neuronal membrane. This postsynaptic hyperpolarization decreases the overall excitability of central nervous system neurons, thereby modulating and reducing the activity of key neuronal circuits responsible for arousal and vigilance.

Dosage and Administration Information

How Noctamide (Lormetazepam) is Used

Noctamide (Lormetazepam) is used according to standard clinical parameters that define the administration route, standard dosing, and maximum duration of treatment. The medication is an oral tablet and is administered at bedtime.

Official Administration and Dosing

The route of administration is oral. Lormetazepam tablets are commonly available in strengths of 0.5 mg and 1.0 mg.

Dosing Parameter Official Instruction
Adult Starting Dose 1 mg as a single dose.
Maximum Single Dose 2 mg, only if clinically warranted.
Frequency and Timing Once daily, taken immediately before going to bed.

Use Conditions and Special Populations

Specific conditions apply for proper administration. Administration requires an uninterrupted sleep period of 7 to 8 hours after taking the tablet.

  • Older Adults: The recommended initial dose is reduced to 0.5 mg as a single dose.
  • Hepatic/Renal Impairment: Dose reduction is considered as lower doses may be sufficient.

Duration and Discontinuation Protocol

The medication is indicated for the shortest time possible, typically a few days to 2 weeks. The entire course of treatment, including the period required for gradual dose reduction, must not exceed 4 weeks. Treatment is discontinued by gradually withdrawing the dose, rather than stopping abruptly.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Noctamide (Lormetazepam)

Evidence for Use in Short-Term Insomnia

Research on Lormetazepam was studied in the context of short-term conditions associated with acute or disruptive episodes of sleeplessness. The evidence is characterized by short-term randomized controlled trials (RCTs). These short-term RCTs, often comparing the agent to a placebo (an inactive substance), research examined outcomes related to both the start and maintenance of sleep.

The main outcomes research examined included objective and subjective measurements of Sleep Onset Latency (the time it takes to fall asleep) and outcomes describing episodic or acute changes in sleep maintenance. Findings describe patterns observed in the studies related to these measured sleep metrics in comparison to control groups. This evidence contributes to the broader evidence landscape regarding how patients with severe, acute insomnia reported their experience over defined, brief time intervals.

Studies in Specific Subgroups

Research examined Lormetazepam in studies focusing on certain groups of patients beyond the general adult population. These studies aimed to understand how the medication was evaluated in individuals with specific characteristics or co-existing health conditions presenting with cycles of stability and flare-ups.

Research in Older Adults

Studies specifically explored Lormetazepam in the older adults population, which often requires a careful assessment of medication effects due to age-related changes in drug processing. The outcomes monitored included those reflecting daily functioning or activity level in addition to the core sleep metrics.

Limitations of Long-Term Studies

There is limited information for long-term outcomes because the original research did not pursue extended duration studies. Consequently, long-term effects are not fully established, and this short-term focus creates a significant gap in the evidence. The studies in this area highlight what is known—and what is still uncertain—about the durability of the effect and monitoring the potential for developing tolerance and physical dependence if administration is continued past the defined brief period.

Key Studies & References

  1. Lormetazepam Sandoz 1 mg/2 mg tablets - Belgian Regulatory Document (ANSM/AFMPS equivalent)
  2. LORAZEPAM-AFT (AFT Pharmaceuticals Pty Ltd) - Australian TGA Public Summary (used to infer TGA regulatory position on benzodiazepines)
  3. Public Database of Medicines (Base de Données Publique des Médicaments) - LORMETAZEPAM ARROW

Frequently Asked Questions (FAQ)

Common questions about Noctamide (FAQ)


Q: Is Noctamide the same type of medicine as Ambien or Lunesta?

Official pharmacological classifications note that Noctamide (Lormetazepam) is a benzodiazepine, a specific class of sedative-hypnotic drugs. Other widely used sleep aids, such as Ambien (Zolpidem) and Lunesta (Eszopiclone), belong to a chemically distinct class, often referred to as Z-drugs. Despite the chemical differences, these classes are both used for the short-term management of insomnia.


Q: How long does the effect of Noctamide typically last?

According to official pharmacokinetic data, Noctamide is considered to have a short-to-intermediate duration of action. The time it takes for the body to eliminate half of the medicine (its elimination half-life) is approximately 10 to 12 hours. This duration is consistent with the product's use as a short-to-intermediate-acting hypnotic, which helps to mitigate residual daytime sedation.


Q: What happens if you stop taking Noctamide suddenly?

Regulatory documents warn that stopping treatment abruptly may lead to the re-emergence of symptoms, known as rebound insomnia, where the original sleep difficulty returns worse than before. After chronic use, there is also a risk of developing a withdrawal syndrome. Because of these risks, official guidelines specify that treatment should be discontinued by gradually reducing the dose over time, rather than stopping abruptly.


Q: What is the difference between Noctamide and a prescription antidepressant?

Noctamide is classified as a hypnotic-sedative drug, and its primary function is to depress the central nervous system to facilitate sleep. Antidepressants, conversely, belong to a psychoactive drug class with the primary function of modulating mood and addressing underlying chemical imbalances. While they treat different conditions, official documents indicate they can interact by potentially enhancing the sedative effects of Noctamide.


Q: What is the general safety classification of Noctamide?

Lormetazepam, the active ingredient in Noctamide, is legally designated as a prescription-only, controlled substance in many countries. Its classification in some national systems, such as Schedule IV in the United States, is primarily anchored by the medicine's established potential for abuse and physical dependence.


Q: Are there official warnings about operating machinery after taking Noctamide?

Yes. Official product information includes specific warnings regarding performance impairment. Residual effects such as sleepiness, dizziness, and impaired psychomotor function may persist into the day after administration. Regulatory warnings indicate that the ability to perform complex tasks like driving or operating machinery may be compromised, leading to specific instructions to avoid these activities.


Q: If I take Noctamide, will I sleep for a full 8 hours?

Official prescribing instructions state that the user must ensure they can dedicate time for an uninterrupted sleep period of 7 to 8 hours after taking the tablet. Regulatory information indicates the drug is used to manage difficulties with sleep onset and maintenance. However, the clinical outcome of achieving a guaranteed 7–8 hours of continuous sleep cannot be promised.


Q: How quickly does Noctamide usually start to work?

Noctamide is pharmacologically characterized as a rapidly absorbed medication. This characteristic supports the instruction for the medicine to be taken immediately before going to bed. The rapid absorption is intended to make the drug's effects promptly available to facilitate sleep onset.


Q: Can you take Noctamide if you drink caffeine during the day?

According to general pharmacological principles for this drug class, substances like caffeine may antagonize, or counteract, the sedative effects of the medicine. Official prescribing advice often references that avoiding caffeine and caffeine-containing products, particularly in the hours leading up to the time the dose is taken, is typically suggested to avoid counteracting the desired sedative effects.


Q: Is it normal to have unusual dreams when taking Noctamide?

Regulatory side effect reports for drugs in the benzodiazepine class sometimes list 'abnormal dreams' or similar sleep disturbances under psychiatric adverse reactions. Although this potential is noted in official documentation, official documentation usually lists this potential in the less common categories of adverse reactions.


Q: Do other medicines, like cold remedies, interact with Noctamide?

Yes. Official information states that the sedative effect of Noctamide can be significantly increased by co-administration with other medicines that cause central nervous system depression. This group includes medicines that contain ingredients often found in over-the-counter cold, flu, and allergy remedies, which are documented as carrying a risk of enhanced central nervous system depression.


Q: How does the mechanism of action of Noctamide differ from natural sleep supplements?

Noctamide's established mechanism of action is precise: it acts directly on the GABA A neurotransmitter receptor in the central nervous system. This action enhances the natural effects of GABA to reduce overall neuronal excitability. This action is highly specific and is based on a defined chemical interaction with the central nervous system.


Q: Why do doctors ask about mental health before prescribing Noctamide?

Official warnings emphasize the need for careful assessment in patients with pre-existing depression, suicidal ideation, or a history of drug or alcohol dependence. Benzodiazepines, the class of drug Noctamide belongs to, may carry a risk of potentially worsening these existing mental health or substance abuse conditions.


Q: What is the risk of overdose associated with Noctamide?

As documented in official overdose sections, the risk is linked to central nervous system depression. Overdose, particularly if combined with other CNS depressants, may result in effects ranging from mild drowsiness and confusion to more severe outcomes like loss of muscle tone, low blood pressure (hypotension), and respiratory depression.


Q: Is Noctamide used to treat other conditions besides insomnia?

Noctamide is formally licensed only for the short-term treatment of severe insomnia. However, its classification as a benzodiazepine means its primary action is multifaceted, producing anxiolytic (anxiety-reducing), muscle relaxant, sedative, and hypnotic effects.


Q: Is there a generic version of Noctamide available?

Yes. Noctamide is a former brand name for the active ingredient Lormetazepam. Lormetazepam is available in generic formulations, which means it is manufactured and distributed by several different companies globally.


Q: What should I do if I forget to take Noctamide one night?

Official patient information leaflets provide clear, non-personalized guidance for missed doses. The regulatory guidance states that a missed dose should not be taken later in the night or the following morning, as this is associated with an increased risk of residual daytime side effects like excessive drowsiness. Taking a double dose is also advised against.


How should Noctamide be stored and disposed of?

Official Storage and Disposal Instructions

Noctamide (lormetazepam) is a controlled substance and must be stored and disposed of according to specific regulatory guidelines to maintain its stability and prevent misuse.

Storage Requirement Condition
Temperature Store at Controlled Room Temperature (20^circ to 25 C or 68^circ to 77 F). Do not freeze.
Protection Keep protected from light and moisture in its tightly closed, original container.
Security Must be kept out of the sight and reach of children and securely stored (locked up).
Disposal Unused or expired medication should be taken to a drug take-back program. If a take-back option is unavailable, follow the specific procedure of mixing the tablets with an undesirable substance (like coffee grounds or dirt) and sealing the mixture before placing it in the household trash. Empty containers must have all personal data obscured before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Noctamide found in:

A-Z Index: